

SKYEPHARMA PLC
Form 6-K
October 10, 2006

**SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of October, 2006

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

Edgar Filing: SKYEPHARMA PLC - Form 6-K

For immediate release

SkyePharma PLC

SkyePharma Appoints Company Secretary

LONDON, ENGLAND, 9 October, 2006 -- SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) today announce Company Secretary.

John is a lawyer with extensive experience in legal and company secretarial roles in listed companies including Medeva, Celltech and Pharmagene. John joined SkyePharma on 1st March this year combining both roles in the Company.

For further information please contact:

SkyePharma PLC	+44 207 491 1
Frank Condella, Chief Executive Officer	
Ken Cunningham, Chief Operating Officer	
Sandra Haughton, US Investor Relations	+1 212 753 57
Buchanan Communications	+44 207 466 5
Tim Anderson / Mark Court / Rebecca Skye Dietrich	
The Trout Group	+1 617 583 13
Seth Lewis	

About SkyePharma

SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technology and more effective drug formulations. There are now twelve approved products incorporating SkyePharma oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. www.skyepharma.com.

END

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ Douglas Parkhill

Name: Douglas Parkhill
Title: Company Secretary

Date: October 9, 2006